Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,294.00
Bid: 12,292.00
Ask: 12,296.00
Change: -70.00 (-0.57%)
Spread: 4.00 (0.033%)
Open: 12,358.00
High: 12,376.00
Low: 12,256.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2020 16:00

RNS Number : 3749L
AstraZeneca PLC
29 April 2020
 

29 April 2020 16:00 BST

 

Results of Annual General Meeting held on 29 April 2020

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019

 

1,061,180,101

99.92

872,215

0.08

1,062,052,316

80.93%

7,121,452

2

To confirm dividends

 

1,058,995,786

99.10

9,598,531

0.90

1,068,594,317

81.43%

579,469

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

1,068,300,235

99.97

312,449

0.03

1,068,612,684

81.43%

560,776

4

To authorise the Directors to agree the remuneration of the Auditor

 

1,067,398,628

99.90

1,086,858

0.10

1,068,485,486

81.42%

687,961

5a

To re-elect Leif Johansson as a Director

 

1,065,113,167

99.69

3,276,071

0.31

1,068,389,238

81.42%

784,805

5b

To re-elect Pascal Soriot as a Director

 

1,067,248,723

99.90

1,033,124

0.10

1,068,281,847

81.41%

892,364

5c

To re-elect Marc Dunoyer as a Director

 

1,060,164,242

99.25

8,056,265

0.75

1,068,220,507

81.40%

952,979

5d

To re-elect Geneviève Berger as a Director

 

882,846,920

83.06

179,994,848

16.94

1,062,841,768

80.99%

6,331,650

5e

To re-elect Philip Broadley as a Director

 

1,066,048,992

99.79

2,190,705

0.21

1,068,239,697

81.41%

933,713

5f

To re-elect Graham Chipchase as a Director

 

1,062,682,507

99.48

5,520,936

0.52

1,068,203,443

81.40%

969,967

5g

To elect Michel Demaré as a Director

 

1,066,252,259

99.82

1,969,593

0.18

1,068,221,852

81.40%

951,558

5h

To re-elect Deborah DiSanzo as a Director

 

1,067,836,362

99.97

351,091

0.03

1,068,187,453

81.40%

985,957

5i

To re-elect Sheri McCoy as a Director

 

1,064,329,862

99.64

3,890,368

0.36

1,068,220,230

81.40%

951,792

5j

To re-elect Tony Mok as a Director

1,067,117,370

99.90

1,066,669

0.10

1,068,184,039

81.40%

989,371

5k

To re-elect Nazneen Rahman as a Director

 

1,067,376,963

99.92

821,467

0.08

1,068,198,430

81.40%

973,592

5l

To re-elect Marcus Wallenberg as a Director

 

955,082,665

89.42

113,060,725

10.58

1,068,143,390

81.40%

1,030,019

6

To approve the Annual Report on Remuneration for the year ended 31 December 2019

 

1,032,308,145

96.65

35,747,783

3.35

1,068,055,928

81.39%

1,118,038

7

To approve the Directors' Remuneration Policy

 

972,774,742

94.71

54,292,376

5.29

1,027,067,118

78.27%

42,106,679

8

To authorise limited political donations

 

1,038,907,152

97.75

23,872,400

2.25

1,062,779,552

80.99%

6,394,668

9

To authorise the Directors to allot shares

 

910,654,650

85.26

157,472,093

14.74

1,068,126,743

81.40%

1,046,979

10

To authorise the Directors to disapply pre-emption rights

 

1,058,066,972

99.23

8,200,338

0.77

1,066,267,310

81.26%

2,906,339

11

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

1,054,711,677

98.92

11,513,414

1.08

1,066,225,091

81.25%

2,948,557

12

To authorise the Company to purchase its own shares

 

1,051,131,060

98.41

16,950,800

1.59

1,068,081,860

81.39%

1,091,896

13

To reduce the notice period for general meetings

 

998,062,805

93.44

70,101,553

6.56

1,068,164,358

81.40%

1,008,865

14

To approve the 2020 Performance Share Plan

1,010,149,491

95.66

45,877,396

4.34

1,056,026,887

80.48%

13,147,356

 

Issued capital

As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGPPURCCUPUGCB
Date   Source Headline
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo
19th Apr 20227:00 amRNSEnhertu granted Priority Review for HER2m NSCLC
1st Apr 20223:00 pmRNSTotal Voting Rights
29th Mar 20227:00 amRNSOndexxya approved in Japan for FXai reversal
28th Mar 20227:00 amRNSEvusheld approved in the EU for COVID-19
25th Mar 20223:30 pmRNSDirector/PDMR Shareholding
24th Mar 20226:00 pmRNSEvusheld Positive EU CHMP Opinion
24th Mar 20227:00 amRNSUpdate on CALLA Phase III trial for Imfinzi
23rd Mar 202211:00 amRNSNotice of AGM
17th Mar 20227:00 amRNSSettlement of patent litigation for Ultomiris
14th Mar 20227:05 amRNSLynparza approved in US for early breast cancer
14th Mar 20227:00 amRNSUpdate on US review of Fasenra in nasal polyps
9th Mar 20223:30 pmRNSDirector/PDMR Shareholding
7th Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20227:00 amRNSAstraZeneca and Neurimmune close deal for NI006
23rd Feb 20227:00 amRNSFiling of Form 20-F with SEC
22nd Feb 202211:00 amRNSChair succession planning update and Annual Report
21st Feb 20227:00 amRNSEnhertu improves PFS and OS in HER2-low BC
16th Feb 20227:00 amRNSSaphnelo approved in EU for SLE
15th Feb 20227:00 amRNSLynparza combo delays progression risk in prostate
11th Feb 20223:30 pmRNSDirector/PDMR Shareholding
10th Feb 20227:00 amRNSAZN: Full year and Q4 2021 results
1st Feb 20223:00 pmRNSTotal Voting Rights
19th Jan 20227:05 amRNSImfinzi improves survival in biliary tract cancer
19th Jan 20227:00 amRNSImfinzi combo shows unprecedented survival in HCC
17th Jan 20227:00 amRNSEnhertu granted Priority Review for breast cancer
7th Jan 20227:00 amRNSAstraZeneca and Neurimmune sign deal for NI006
5th Jan 20227:00 amRNSTransfer of rights to Eklira, Duaklir completed
4th Jan 20223:00 pmRNSTotal Voting Rights
29th Dec 20217:00 amRNSAstraZeneca and Ionis close eplontersen deal
21st Dec 20217:00 amRNSUltomiris accepted for FDA Priority Review for gMG
20th Dec 20217:05 amRNSTezspire approved in the US for severe asthma
20th Dec 20217:00 amRNSSaphnelo recommended for EU approval for SLE
15th Dec 20213:00 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSEvusheld US FDA EUA
7th Dec 20217:00 amRNSAstraZeneca, Ionis to collaborate on eplontersen
1st Dec 20213:00 pmRNSBlock listing Interim Review
1st Dec 20213:00 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSLynparza granted FDA Priority Review for OlympiA
15th Nov 20214:00 pmRNSDirector/PDMR Shareholding
12th Nov 20217:00 amRNSAZN: Year to date and Q3 2021 results
1st Nov 20213:00 pmRNSTotal Voting Rights
1st Nov 20217:00 amRNSAstraZeneca to transfer rights to Eklira, Duaklir
25th Oct 20217:00 amRNSImfinzi improved survival in biliary tract cancer
18th Oct 20217:00 amRNSAZ recommends ADS holders reject mini-tender offer
15th Oct 20217:00 amRNSImfinzi & tremelimumab improved OS in liver cancer
11th Oct 20217:00 amRNSAZD7442 PhIII trial positive in COVID outpatients

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.